Baillie Gifford & Co
AXDX icon

Baillie Gifford & Co’s Accelerate Diagnostics AXDX Stock Holding History

Baillie Gifford & Co’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-42
Closed -$293 – 308
2023
Q1 		$293 Hold
42
– – ﹤0.01% 452
2022
Q4 		$295 Hold
42
– – ﹤0.01% 486
2022
Q3 		$1K Hold
42
– – ﹤0.01% 477
2022
Q2 		$0 Hold
42
– – ﹤0.01% 492
2022
Q1 		$1K Hold
42
– – ﹤0.01% 492
2021
Q4 		$2K Hold
42
– – ﹤0.01% 494
2021
Q3 		$2K Hold
42
– – ﹤0.01% 488
2021
Q2 		$3K Hold
42
– – ﹤0.01% 465
2021
Q1 		$3K Buy
42
+5
+14% +$507 ﹤0.01% 441
2020
Q4 		$3K Buy
+37
New +$3.31K ﹤0.01% 422

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co's AXDX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Accelerate Diagnostics (AXDX) in Q2 2023, closing a stake of 42 shares — an estimated $293 sold.

Baillie Gifford & Co first reported a position in AXDX in Q4 2020 and held it in 10 quarters. The position peaked at $3K in Q2 2021. 51 funds tracked by Wall St. Rank hold AXDX as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Accelerate Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 42 Accelerate Diagnostics shares in Q2 2023, an estimated $293.
  • Baillie Gifford & Co first reported a position in Accelerate Diagnostics in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Accelerate Diagnostics position peaked at $3K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.